RxDoctor Payments DataLook up a doctor →

Russell Branum, MD

Rheumatology · Fort Smith, ARNPI 1629065685

Payments from drug & device makers

$101,729in general payments, 2019–2025

Across 1,411 payments — averaging $72.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$40K
  • Amgen$36K
  • Pfizer$9K
  • Johnson & Johnson$4K
  • UCB, Inc.$3K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $8K from 21 others

What the payments were for

  • Consulting fees$6,3306%
  • Speaking & faculty fees$62,92062%
  • Travel & lodging$5,9966%
  • Food & beverage$26,06426%
  • Education$4190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,729 in reported general payments places this provider in the 85th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$4,178,410
Medicare patients
919
Services billed
282,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab32$226,642
Enbrel MiniEtanercept22$157,224
RinvoqUpadacitinib22$145,597
XeljanzTofacitinib Citrate17$93,012
Hydroxychloroquine Sulfate307$11,572
SavellaMilnacipran Hcl18$9,260
Leflunomide154$7,761
MethotrexateMethotrexate Sodium369$7,441
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen104$3,001
Gabapentin193$2,738
Duloxetine Hcl112$2,418
Celecoxib92$2,099
Cyclobenzaprine Hcl85$1,979
Mycophenolate Mofetil27$1,969
Pilocarpine Hcl25$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$39,968$154,85740 claims
PfizerXeljanz$9,175$93,01217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 rheumatology providers in Arkansas.

Other rheumatology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →